Sarcoidosis

1999, Am J Respir Crit Care Med, 160, 736, 10.1164/ajrccm.160.2.ats4-99

Baughman, 2003, Sarcoidosis, Lancet, 361, 1111, 10.1016/S0140-6736(03)12888-7

Baughman, 2011, A concise review of pulmonary sarcoidosis, Am J Respir Crit Care Med, 183, 573, 10.1164/rccm.201006-0865CI

Iannuzzi, 2011, Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics, JAMA, 305, 391, 10.1001/jama.2011.10

Hillerdal, 1984, Sarcoidosis: epidemiology and prognosis. A 15-year European study, Am Rev Respir Dis, 130, 29

Morimoto, 2008, Epidemiology of sarcoidosis in Japan, Eur Respir J, 31, 372, 10.1183/09031936.00075307

Varron, 2012, Late-onset sarcoidosis: a comparative study, Medicine (Baltimore), 91, 137, 10.1097/MD.0b013e3182569f91

Deubelbeiss, 2010, Prevalence of sarcoidosis in Switzerland is associated with environmental factors, Eur Respir J, 35, 1088, 10.1183/09031936.00197808

Newman, 2004, A case control etiologic study of sarcoidosis: environmental and occupational risk factors, Am J Respir Crit Care Med, 170, 1324, 10.1164/rccm.200402-249OC

Crowley, 2011, “Sarcoid like” granulomatous pulmonary disease in World Trade Center disaster responders, Am J Ind Med, 54, 175, 10.1002/ajim.20924

Perlman, 2011, Short-term and medium-term health effects of 9/11, Lancet, 378, 925, 10.1016/S0140-6736(11)60967-7

Rybicki, 2001, Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS), Am J Respir Crit Care Med, 164, 2085, 10.1164/ajrccm.164.11.2106001

Sverrild, 2008, Heredity in sarcoidosis: a registry-based twin study, Thorax, 63, 894, 10.1136/thx.2007.094060

Müller-Quernheim, 2008, Genetics of sarcoidosis, Clin Chest Med, 29, 391, 10.1016/j.ccm.2008.03.007

Chen, 2008, Etiology of sarcoidosis, Clin Chest Med, 29, 365, 10.1016/j.ccm.2008.03.011

Bafica, 2005, TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis, J Exp Med, 202, 1715, 10.1084/jem.20051782

Kalis, 2005, Requirement for TLR9 in the immunomodulatory activity of Propionibacterium acnes, J Immunol, 174, 4295, 10.4049/jimmunol.174.7.4295

Chen, 2010, Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2, Am J Respir Crit Care Med, 181, 360, 10.1164/rccm.200905-0696OC

Chen, 2011, Innate pathways shape sarcoidosis signaling: from bugs to drugs, Am J Respir Crit Care Med, 183, 425, 10.1164/rccm.201010-1570ED

Swaisgood, 2011, Development of a sarcoidosis murine lung granuloma model using Mycobacterium superoxide dismutase A peptide, Am J Respir Cell Mol Biol, 44, 166, 10.1165/rcmb.2009-0350OC

Ishige, 1999, Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis, Lancet, 354, 120, 10.1016/S0140-6736(98)12310-3

McCaskill, 2006, Pulmonary immune responses to Propionibacterium acnes in C57BL/6 and BALB/c mice, Am J Respir Cell Mol Biol, 35, 347, 10.1165/rcmb.2005-0285OC

Zissel, 2010, Immunologic response of sarcoidosis, Semin Respir Crit Care Med, 31, 390, 10.1055/s-0030-1262208

Rastogi, 2011, Dysregulation of p38 and MKP-1 in response to NOD1/TLR4 stimulation in sarcoid bronchoalveolar cells, Am J Respir Crit Care Med, 183, 500, 10.1164/rccm.201005-0792OC

Wiken, 2009, Higher monocyte expression of TLR2 and TLR4, and enhanced pro-inflammatory synergy of TLR2 with NOD2 stimulation in sarcoidosis, J Clin Immunol, 29, 78, 10.1007/s10875-008-9225-0

Pignatti, 2006, Role of the chemokine receptors CXCR3 and CCR4 in human pulmonary fibrosis, Am J Respir Crit Care Med, 173, 310, 10.1164/rccm.200502-244OC

Facco, 2011, Sarcoidosis is a Th1/Th17 multisystem disorder, Thorax, 66, 144, 10.1136/thx.2010.140319

Miyara, 2006, The immune paradox of sarcoidosis and regulatory T cells, J Exp Med, 203, 359, 10.1084/jem.20050648

Prasse, 2010, Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis, Am J Respir Crit Care Med, 182, 540, 10.1164/rccm.200909-1451OC

Zissel, 1996, Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis, Am J Respir Crit Care Med, 154, 713, 10.1164/ajrccm.154.3.8810610

Baughman, 2006, Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement, Am J Respir Crit Care Med, 174, 795, 10.1164/rccm.200603-402OC

Berlin, 1997, HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis, Am J Respir Crit Care Med, 156, 1601, 10.1164/ajrccm.156.5.9704069

Grunewald, 2010, Major histocompatibility complex class II transactivator gene polymorphism: associations with Lofgren's syndrome, Tissue Antigens, 76, 96

Sato, 2010, Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups, Hum Mol Genet, 19, 4100, 10.1093/hmg/ddq325

Rossman, 2003, HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites, Am J Hum Genet, 73, 720, 10.1086/378097

Veltkamp, 2012, Genetic variation in the Toll-like receptor gene cluster (TLR10-TLR1-TLR6) influences disease course in sarcoidosis, Tissue Antigens, 79, 25, 10.1111/j.1399-0039.2011.01808.x

Valentonyte, 2005, Sarcoidosis is associated with a truncating splice site mutation in BTNL2, Nat Genet, 37, 357, 10.1038/ng1519

Hofmann, 2008, Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis, Nat Genet, 40, 1103, 10.1038/ng.198

Nguyen, 2006, BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation, J Immunol, 176, 7354, 10.4049/jimmunol.176.12.7354

Lockstone, 2010, Gene set analysis of lung samples provides insight into pathogenesis of progressive, fibrotic pulmonary sarcoidosis, Am J Respir Crit Care Med, 181, 1367, 10.1164/rccm.200912-1855OC

Crouser, 2009, Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis, Am J Respir Crit Care Med, 179, 929, 10.1164/rccm.200803-490OC

Navani, 2012, Endobronchial ultrasound-guided transbronchial needle aspiration prevents mediastinoscopies in the diagnosis of isolated mediastinal lymphadenopathy: a prospective trial, Am J Respir Crit Care Med, 186, 255, 10.1164/rccm.201203-0393OC

Plit, 2012, Rapid cytological analysis of endobronchial ultrasound-guided aspirates in sarcoidosis, Eur Respir J

Mostard, 2011, Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis, Respir Med, 105, 1917, 10.1016/j.rmed.2011.08.012

Sobic-Saranovic, 2012, The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis, J Nucl Med, 53, 1543, 10.2967/jnumed.112.104380

Mostard, 2012, A predictive tool for an effective use of 18F-FDG PET in assessing activity of sarcoidosis, BMC Pulm Med, 12, 57, 10.1186/1471-2466-12-57

Keijsers, 2011, 18F-FDG PET as a predictor of pulmonary function in sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 28, 123

Youssef, 2012, The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience, J Nucl Med, 53, 241, 10.2967/jnumed.111.090662

Soussan, 2013, Clinical value of a high-fat and low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis, J Nucl Cardiol, 20, 120, 10.1007/s12350-012-9653-3

Drent, 2012, Sarcoidosis-associated fatigue, Eur Respir J, 40, 255, 10.1183/09031936.00002512

Hoitsma, 2011, The small fiber neuropathy screening list: construction and cross-validation in sarcoidosis, Respir Med, 105, 95, 10.1016/j.rmed.2010.09.014

Baughman, 2010, Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation, Chest, 138, 1078, 10.1378/chest.09-2002

Patel, 2013, The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status, Thorax, 68, 57, 10.1136/thoraxjnl-2012-201962

Judson, 2003, The diagnostic pathway to sarcoidosis, Chest, 123, 406, 10.1378/chest.123.2.406

Criado, 2010, Pulmonary sarcoidosis: typical and atypical manifestations at high-resolution CT with pathologic correlation, Radiographics, 30, 1567, 10.1148/rg.306105512

Mana, 2012, Skin manifestations of sarcoidosis, Presse Med, 41, e355, 10.1016/j.lpm.2012.02.046

Judson, 2007, Extrapulmonary sarcoidosis, Semin Respir Crit Care Med, 28, 83, 10.1055/s-2007-970335

Herbort, 2009, International criteria for the diagnosis of ocular sarcoidosis: results of the first international workshop on ocular sarcoidosis (IWOS), Ocul Immunol Inflamm, 17, 160, 10.1080/09273940902818861

Bodaghi, 2012, Ocular sarcoidosis, Presse Med, 41, e349, 10.1016/j.lpm.2012.04.004

Cremers, 2012, Liver-test abnormalities in sarcoidosis, Eur J Gastroenterol Hepatol, 24, 17, 10.1097/MEG.0b013e32834c7b71

Hamzeh, 2012, Management of cardiac sarcoidosis in the United States: a Delphi study, Chest, 141, 154, 10.1378/chest.11-0263

Patel, 2009, Detection of myocardial damage in patients with sarcoidosis, Circulation, 120, 1969, 10.1161/CIRCULATIONAHA.109.851352

Nozaki, 2012, Isolated neurosarcoidosis: case series in 2 sarcoidosis centers, Neurologist, 18, 373, 10.1097/NRL.0b013e3182704d04

Hoitsma, 2004, Neurosarcoidosis: a clinical dilemma, Lancet Neurol, 3, 397, 10.1016/S1474-4422(04)00805-1

Cohen-Aubart, 2010, Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study, Medicine (Baltimore), 89, 133, 10.1097/MD.0b013e3181d5c6b4

Mahevas, 2009, Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients, Medicine (Baltimore), 88, 98, 10.1097/MD.0b013e31819de50f

Sweiss, 2010, Rheumatologic manifestations of sarcoidosis, Semin Respir Crit Care Med, 31, 463, 10.1055/s-0030-1262214

Nunes, 2012, Imaging of sarcoidosis of the airways and lung parenchyma and correlation with lung function, Eur Respir J, 40, 750, 10.1183/09031936.00025212

Costabel, 2010, Diagnostic modalities in sarcoidosis: BAL, EBUS, and PET, Semin Respir Crit Care Med, 31, 404, 10.1055/s-0030-1262207

Park, 2008, Common variable immunodeficiency: a new look at an old disease, Lancet, 372, 489, 10.1016/S0140-6736(08)61199-X

Müller-Quernheim, 2006, Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients, Eur Respir J, 27, 1190, 10.1183/09031936.06.00112205

Baughman, 2009, Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation, Chest, 136, 526, 10.1378/chest.08-1876

Nunes, 2007, Imaging in sarcoidosis, Semin Respir Crit Care Med, 28, 102, 10.1055/s-2007-970336

Erdal, 2012, Quantitative computerized two-point correlation analysis of lung CT scans correlates with pulmonary function in pulmonary sarcoidosis, Chest, 142, 1589, 10.1378/chest.11-2027

Baughman, 2007, Six-minute walk test and health status assessment in sarcoidosis, Chest, 132, 207, 10.1378/chest.06-2822

Marcellis, 2013, Is there an added value of cardiopulmonary exercise testing in sarcoidosis patients?, Lung, 191, 43, 10.1007/s00408-012-9432-6

Wallaert, 2011, Reduction of maximal oxygen uptake in sarcoidosis: relationship with disease severity, Respiration, 826, 501, 10.1159/000330050

Lopes, 2012, Cardiopulmonary exercise testing variables as predictors of long-term outcome in thoracic sarcoidosis, Braz J Med Biol Res, 45, 256, 10.1590/S0100-879X2012007500018

Kollert, 2011, The impact of gas exchange measurement during exercise in pulmonary sarcoidosis, Respir Med, 105, 122, 10.1016/j.rmed.2010.09.007

Nunes, 2012, Pulmonary hypertension complicating sarcoidosis, Presse Med, 41, e303, 10.1016/j.lpm.2012.04.003

Treglia, 2011, Emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: a systematic review, Sarcoidosis Vasc Diffuse Lung Dis, 28, 87

Schuller, 2011, Electrocardiographic characteristics in patients with pulmonary sarcoidosis indicating cardiac involvement, J Cardiovasc Electrophysiol, 22, 1243, 10.1111/j.1540-8167.2011.02099.x

Zajicek, 1999, Central nervous system sarcoidosis–diagnosis and management, QJM, 92, 103, 10.1093/qjmed/92.2.103

Hoitsma, 2002, Small fibre neuropathy in sarcoidosis, Lancet, 359, 2085, 10.1016/S0140-6736(02)08912-2

De Vries, 2004, Measuring fatigue in sarcoidosis: the fatigue assessment scale (FAS), Br J Health Psychol, 9, 279, 10.1348/1359107041557048

Elfferich, 2010, Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment, Respiration, 80, 212, 10.1159/000314225

De Vries, 2010, Quality of life in sarcoidosis: assessment and management, Semin Respir Crit Care Med, 31, 485, 10.1055/s-0030-1262216

Biller, 2006, Genotype-corrected reference values for serum angiotensin-converting enzyme, Eur Respir J, 28, 1085, 10.1183/09031936.00050106

Bargagli, 2013, Human chitotriosidase: a sensitive biomarker of sarcoidosis, J Clin Immunol, 33, 264, 10.1007/s10875-012-9754-4

Bargagli, 2011, Analysis of serum amyloid A in sarcoidosis patients, Respir Med, 105, 775, 10.1016/j.rmed.2010.12.010

Mahevas, 2011, Association of sarcoidosis and immune thrombocytopenia: presentation and outcome in a series of 20 patients, Medicine (Baltimore), 90, 269, 10.1097/MD.0b013e31822618b3

Handa, 2010, Significance of plasma NT-proBNP levels as a biomarker in the assessment of cardiac involvement and pulmonary hypertension in patients with sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 27, 27

Baba, 2012, Usefulness of high-sensitive cardiac troponin T for evaluating the activity of cardiac sarcoidosis, Int Heart J, 53, 287, 10.1536/ihj.53.287

Neville, 1983, Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients, QJM, 52, 525

Prasse, 2008, Phenotyping sarcoidosis from a pulmonary perspective, Am J Respir Crit Care Med, 177, 330, 10.1164/rccm.200705-742OC

Wasfi, 2006, A new tool to assess sarcoidosis severity, Chest, 129, 1234, 10.1378/chest.129.5.1234

Ziegenhagen, 2003, Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis, Eur Respir J, 21, 407, 10.1183/09031936.03.00010403

Keir, 2010, Assessing pulmonary disease and response to therapy: which test?, Semin Respir Crit Care Med, 31, 409, 10.1055/s-0030-1262209

Zappala, 2011, Optimal scoring of serial change on chest radiography in sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 28, 130

Judson, 2008, The utility of the chest radiograph in diagnosing exacerbations of pulmonary sarcoidosis, Respirology, 13, 97, 10.1111/j.1440-1843.2007.01206.x

Rizzato, 1998, The late follow-up of chronic sarcoid patients previously treated with corticosteroids, Sarcoidosis Vasc Diffuse Lung Dis, 15, 52

King, 1992, Restrictive lung disease in pregnancy, Clin Chest Med, 13, 607, 10.1016/S0272-5231(21)01129-1

Nardi, 2012, Stage IV sarcoidosis: comparison of survival with the general population and causes of death, Eur Respir J, 38, 1368, 10.1183/09031936.00187410

Gribbin, 2006, Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK, Thorax, 61, 980, 10.1136/thx.2006.062836

Swigris, 2011, Sarcoidosis-related mortality in the United States from 1988 to 2007, Am J Respir Crit Care Med, 183, 1524, 10.1164/rccm.201010-1679OC

Shorr, 2003, Predicting mortality in patients with sarcoidosis awaiting lung transplantation, Chest, 124, 922, 10.1016/S0012-3692(15)37649-2

Swigris, 2011, Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007, Chest, 140, 1261, 10.1378/chest.11-0324

Schutt, 2010, Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study, Respir Med, 104, 717, 10.1016/j.rmed.2009.12.009

Müller-Quernheim, 1999, Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen, Eur Respir J, 14, 1117, 10.1183/09031936.99.14511179

Sahoo, 2011, Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis, Eur Respir J, 38, 1145, 10.1183/09031936.00195010

Kouba, 2003, Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis, Br J Dermatol, 148, 147, 10.1046/j.1365-2133.2003.05042.x

Park, 2009, Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 26, 121

Zabel, 1997, Pentoxifylline in treatment of sarcoidosis, Am J Respir Crit Care Med, 155, 1665, 10.1164/ajrccm.155.5.9154873

Judson, 2006, The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 23, 51

Baughman, 2008, Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them, Sarcoidosis Vasc Diffuse Lung Dis, 25, 76

Baltzan, 1999, Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis, Am J Respir Crit Care Med, 160, 192, 10.1164/ajrccm.160.1.9809024

Bradley, 2008, Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society, Thorax, 63, v1

Gibson, 1996, British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment, Thorax, 51, 238, 10.1136/thx.51.3.238

Paramothayan, 2005, Corticosteroids for pulmonary sarcoidosis, Cochrane Database Syst Rev, 2, 10.1002/14651858.CD001114.pub2

Paramothayan, 2006, Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis, Cochrane Database Syst Rev, 3, 10.1002/14651858.CD003536.pub2

Baughman, 2005, Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial, Chest, 128, 1062, 10.1016/S0012-3692(15)50471-6

Rossman, 2006, A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 23, 201

Lower, 2008, Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue, Chest, 133, 1189, 10.1378/chest.07-2952

Judson, 1999, An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment, Chest, 115, 1158, 10.1378/chest.115.4.1158

Pietinalho, 2002, Early treatment of stage II sarcoidosis improves 5-year pulmonary function, Chest, 121, 24, 10.1378/chest.121.1.24

Baughman, 2000, Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial, Sarcoidosis Vasc Diffuse Lung Dis, 17, 60

Baughman, 2004, Leflunomide for chronic sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 21, 43

Sweiss, 2010, C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 27, 49

Sodhi, 2009, Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis, Respir Med, 103, 268, 10.1016/j.rmed.2008.08.016

Stagaki, 2009, The treatment of lupus pernio: results of 116 treatment courses in 54 patients, Chest, 135, 468, 10.1378/chest.08-1347

Utz, 2003, Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis, Chest, 124, 177, 10.1378/chest.124.1.177

Erckens, 2012, Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis, Graefes Arch Clin Exp Ophthalmol, 250, 713, 10.1007/s00417-011-1844-0

Lower, 2012, Rituximab for refractory granulomatous eye disease, Clin Ophthalmol, 6, 1613

Baughman, 2012, Efficacy and safety of apremilast in chronic cutaneous sarcoidosis, Arch Dermatol, 148, 262, 10.1001/archdermatol.2011.301

Corte, 2011, Pulmonary hypertension in sarcoidosis: a review, Respirology, 16, 69, 10.1111/j.1440-1843.2010.01872.x

Burke, 2010, Calcium and vitamin D in sarcoidosis: how to assess and manage, Semin Respir Crit Care Med, 31, 474, 10.1055/s-0030-1262215

Shah, 2007, Lung transplantation in sarcoidosis, Semin Respir Crit Care Med, 28, 134, 10.1055/s-2007-970339

Collins, 2001, Frequency and CT findings of recurrent disease after lung transplantation, Radiology, 219, 503, 10.1148/radiology.219.2.r01ma12503